Stay updated with breaking news from Drug Development Summit. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The data will be presented at the Annual ALS Drug Development Summit, which is focused on identifying transformative ALS targets, seeking translational biomarkers and propelling more clinical...
BioVie Inc (NASDAQ:BIVI) announced that it has presented data showing its lead drug asset NE3107 may restore homeostasis via specific genes associated with...
Latest on NKGen Biotech Inc (NASDAQ: NKGN) as shares surge 25.2% on high volume. Insights into NK cell therapy for neurodegenerative diseases. Developments in Parkinson's and Alzheimer's treatments.
Although FAK inhibition alone has displayed modest activity to date, there is interest in developing FAK-targeted therapies for combination regimens.
NKGen Biotech Inc (NASDAQ:NKGN) shares traded higher on Monday, with a strong session volume of 19.25 million, compared to an average 100-day volume of 2.85 million, according to data from Benzinga Pro. However, there is no news to justify the +20% increase in the stock price. NKGen Biotech will present details about its NK cell therapy for neurodegenerative disease, review its preclinical data for Parkinson’s disease, and highlight clinical safety and efficacy data from the recently completed P